The FDA approved Leqembi IQLIK (lecanemab-irmb) as an at-home starting dose for early Alzheimer's disease on July 13, 2026. People with mild cognitive impairment, an early stage with clear memory problems that do not prevent daily tasks, can ask an Alzheimer's specialist about eligibility, home use, risks, and follow-up. Leqembi IQLIK is a subcutaneous form, meaning an injection under the skin with an autoinjector, that can be started at home by patients or care partners. According to the FDA approval notice, the FDA approval notice it replaces the initial biweekly IV infusions at an infusion center for eligible patients.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Read the official guidance from Prnewswire — Use this primary source to verify the official guidance.
Table of Contents
- Are you in the approved starting group?
- How does the at-home start work?
- What safety monitoring still needs a clinic?
- What should you ask about access and timing?
Are you in the approved starting group?
Treatment is approved for adults with early Alzheimer's disease. That means mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid-beta pathology, a buildup of amyloid protein in the brain shown by testing.
According to Eisai and Biogen, the initiation approval announcement the approved group matches the trial population. Ask your specialist what test confirmed amyloid in your case and whether your diagnosis still fits. Use this check at your visit:.
- What is my exact diagnosis and stage?
- How was amyloid-beta confirmed?
- Do other health conditions or medicines affect eligibility?
How does the at-home start work?
The starting regimen is 500 mg once weekly as two back-to-back 250-mg autoinjector injections. According to Eisai and Biogen, the company dosing statement each injection takes about 15 seconds to complete. A patient or care partner gives the injections at home after training.
Ask who will teach the technique, how to store and handle the autoinjectors, and what to do after a missed or partial dose. Ask also about support between visits. Good questions are who to call for injection problems, what symptoms need same-day care, and how often the clinic will review your progress.
What safety monitoring still needs a clinic?
Lecanemab carries a boxed warning for amyloid-related imaging abnormalities, called ARIA. ARIA-E is fluid or swelling in the brain, and ARIA-H is small bleeding spots, both found on MRI scans. Home dosing does not remove the need for MRI scans and clinical checks.
Ask how many MRIs you will need, when they occur, and what symptoms should prompt an urgent scan or exam. Bring a care partner to this talk. Ask what headache, confusion, vision change, dizziness, or weakness should trigger a call, and where to seek urgent care on nights and weekends.
What should you ask about access and timing?
Subcutaneous Leqembi IQLIK was first approved only for maintenance after 18 months of IV treatment, and the 2026 action allows patients to start directly with injections. Ask whether starting at home changes your wait time, travel needs, or infusion-center plan. Eisai and Biogen planned a U.S.
launch in late August 2026 through specialty pharmacy. Ask whether your clinic orders through that channel, how prior approval works, and when your first shipment and training can occur. End the visit with clear actions and dates. Ask for the prescription path, the MRI schedule, the next specialist visit, and written home-injection and warning-sign instructions.
